Aligos Therapeutics to Present at Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”) is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat Addressing unmet medical needs in the liver and viral diseases, today announced that Aligos Chairman and Chief Executive Officer Lawrence M. Blatt, Ph.D., MBA, and the Aligos management team will present at the 2023 Piper Sandler Healthcare Conference in New York on Thursday, November 30 , 2023 at 12:30 p.m. ET.

Piper Sandler Healthcare Conference Information:

A replay of the meeting will be available for 90 days following the meeting through the Aligos Investors section of the website at https://investor.aligos.com/.

The Aligos management team will also participate in investor 1×1 sessions during the conference. Please contact your Piper Sandler representative to schedule a one-on-one meeting with Aligos during the conference.

About Arrigos

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 with a mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to leverage its team’s deep expertise and decades of drug development experience in liver and viral diseases to discover and develop drugs targeting non-alcoholic steatohepatitis (NASH) and viruses with high unmet medical need, such as potential best treatments for coronaviruses and chronic viruses). Hepatitis B (CHB).

Media Contact
Veronica Eames
Life Sciences Newsletter
Veames@lifescicomms.com

Investor Contact
Dr. Corey Davis
life sciences consultant
+1 212 915 2577
cdavis@lifesciadvisors.com